^
Association details:
| Biomarker: | FGFR4 G388R + NOS3 rs2070744 |
|---|---|
| Cancer: | Hepatocellular Cancer |
| Drug: | Lenvima (lenvatinib) (c-KIT inhibitor, FGFR inhibitor, VEGFR inhibitor, RET inhibitor, PDGFR α antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Influence of NOS3 rs2070744 genotypes on hepatocellular carcinoma patients treated with lenvatinib
Published date:
10/13/2020
Excerpt:
However, the SNP combination pattern of the NOS3 rs2070744 and FGFR4 rs351855 genotypes may be helpful as treatment effect predictors and prognostic factors for HCC patients treated with lenvatinib. The SNP combination pattern of the NOS3 rs2070744 TC/CC and FGFR4 rs351855 CT/TT genotypes was significantly associated with both PFS (HR 2.95; 95% CI 1.27–6.86; p = 0.012) and OS (HR 3.29; 95% CI 1.01–10.74; p = 0.049), respectively.
DOI:
doi.org/10.1038/s41598-020-73930-3
